Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Dropping Therapeutic RNAi, Cenix Takes Target Validation Downstream

Dropping Therapeutic RNAi, Cenix Takes Target Validation Downstream

Oct 10, 2003
Premium

In April, after reviewing a business model that incorporated RNAi-based drug development, Cenix Biosciences made the decision to refocus strictly on offering RNAi reagent design, target discovery, and target validation services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Another Study for AstraZeneca

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna to Seek EUA

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

To Spot it Earlier

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

PLOS Papers on Glioblastoma in Lebanon, Syndromic Gene PheWAS, Newborn Cytokine GWAS

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
03
Featured Webinar

Leveraging Multi-Omic Approaches to Understand Disease Stem Cells in Myeloid Malignancies

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Featured Webinar

Accelerating Forward Engineering and Genome Discovery with CRISPR: E. Coli Case Studies

Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology. 

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.